MARKETSnap
  • Market Snapshots
    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
    • P/E Ratios
      • Large Caps
      • Absolute
      • Total Market PE
    • Stocks Performance
      • Large Caps
      • Absolute
    • Industries Performance
      • Industry
      • Sector
  • Analyze Stock
    • Analyze a stockAnalyze ANIK →
    • FindStock Picks / Stock Screener
    • Value · ANIKIntrinsic Value Calculator
    • Invest · ANIKInvestment Case
    • Hold · ANIK5-Year Outlook
  • Learn
  • Calendar
  • Investment Compounding
    Calculator
  • Investing Philosophy
  • More
    • Charts
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
ANIK stock logo

ANIK

Anika Therapeutics, Inc.

$13.23
-0.05
 (-0.38%)
Exchange:  NASDAQ
Market Cap:  177.22M
Shares Outstanding:  14.339M
Delayed data
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  HealthcareView sector performance
Industry:  Medical – SpecialtiesView industry performance
   
CEO:  Stephen D. Griffin
Full Time Employees:  235
Address: 
32 Wiggins Avenue
Bedford
MA
1730
US
Website:  https://www.anika.com
Anika Therapeutics, Inc. is a company dedicated to joint preservation, innovating and providing early intervention orthopedic care across the globe, including the United States and Europe. Their core focus areas include osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and advanced bone-preserving joint technologies. All of Anika’s products are developed, manufactured, and commercialized utilizing their proprietary hyaluronic acid (HA) technology platform. Their comprehensive product lines feature an OA pain management family, which includes established treatments like Monovisc, Orthovisc, Cingal, and Hyvisc, all designed to alleviate discomfort from osteoarthritis. The company’s joint preservation and restoration offerings are extensive, comprising approximately 150 bone-sparing joint technology products, alongside solutions for sports medicine soft tissue repair and orthopedic regenerative therapies. Furthermore, Anika leverages its HA expertise in a non-orthopedic product family, developing applications such as adhesion barriers, advanced wound care products, ophthalmic solutions, and ear, nose, and throat treatments. Anika Therapeutics, Inc. was established in 1983 and is based in Bedford, Massachusetts.

Click to read more…

Revenue Segmentation

Revenue by type

Revenue by region

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Log in — it's free

Industry Peers

TICKERCOMPANYMKT CAPP/EFWD P/EROIC
ANANIK logoANIKAnika Therapeutics, Inc.177.2M—11.9-0.4%
LALAB logoLABStandard BioTools Inc.249.1M——-6.6%
APAPYX logoAPYXApyx Medical Corporation101.1M——-6.4%
NYNYXH logoNYXHNyxoah S.A.82.0M——-68.1%
SKSKIN logoSKINSkinHealth Systems Inc.76.7M——2.1%
BWBWAY logoBWAYBrainsWay Ltd.332.6M34.729.29.3%

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Log in — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2026/04/29 — Q1 quarter 2026

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Log in — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue120,792119,907112,819
Gross Profit82,53275,99863,807
EBITDA17,3735,357-3,578
Operating Income844-5,101-11,051
Net Income-82,667-56,385-10,880

Log in to continue

Log in to see the income statement and 10 historical years.

Log in — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets270,632202,740190,270
Total Liabilities58,36748,75146,805
Total Stockholders Equity212,265153,989143,465
Total Debt29,03725,93224,196
Cash and Cash Equivalents72,86755,62957,481

Log in to continue

Log in to see the balance sheet and 10 historical years.

Log in — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow-1,7885,40311,188
Capital Expenditure-5,427-7,734-6,826
Free Cash Flow-7,215-2,3314,362
Net Income-82,667-56,385-10,880
Net Change in Cash-13,460-15,708322

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Log in — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Low)142,557.223Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (High)143,239.534Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Avg)142,900Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Low)Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (High)Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Avg)Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Low)0Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (High)0Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Avg)0Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Low)66,885.819Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (High)67,205.949Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Avg)67,046.645Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Avg)0Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (High)0Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Low)0Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated Revenue)1Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated EPS)0Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Research Access to see up to 5 years of analyst estimates.

Create a free account

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
119.907M  ?P/S
 (TTM)
: 
1.44
?Net Income
 (TTM)
: 
-56.385M  ?P/E
 (TTM)
: 
-102.16
?Enterprise Value
 (TTM)
: 
156.828M  ?EV/FCF
 (TTM)
: 
68.33
?Dividend Yield
 (TTM)
: 
0%  ?Payout Ratio
 (TTM)
: 
0%
?ROE
 (TTM)
: 
-1.28%  ?ROIC
 (TTM)
: 
-0.41%
?Net Debt
 (TTM)
: 
-29.697M  ?Debt/Equity
 (TTM)
: 
0.18
?P/B
 (TTM)
: 
1.29  ?Current Ratio
 (TTM)
: 
3.86

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Log in — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Research Access for high/low estimates and the interactive table.

Forward P/E 1YResearch AccessResearch AccessResearch AccessResearch Access
11.92Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Research Access for forward P/E high/low estimates and the full multi-year table.

Create a free account

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

Based on current fundamentals and analyst forecasts, MarketSnap estimates ANIK intrinsic value between $19.75 – $21.52 per share. This depends on revenue growth, margins, and discount rate.

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.


Calculate ANIK Intrinsic Value

Common questions about ANIK valuation

Is Anika Therapeutics, Inc. (ANIK) overvalued or undervalued right now?

MarketSnap estimates intrinsic value for Anika Therapeutics, Inc. (ANIK) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is ANIK a buy, hold, or sell for long-term investors?

MarketSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether ANIK trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is ANIK’s P/E ratio?

You can see ANIK’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for ANIK?

MarketSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MarketSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is ANIK a good long-term investment?

Whether ANIK fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MarketSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

Research tools for Anika Therapeutics, Inc.

  • Anika Therapeutics, Inc. intrinsic value calculatorEstimate what the business is worth
  • Anika Therapeutics, Inc. 5-year outlookWhat has to go right, and what could go wrong
ANIK

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

-0.38
MarketSnap

Trading Metrics:

Open: 13.41   Previous Close: 13.28
Day Low: 12.98   Day High: 13.68
Year Low: 9.01   Year High: 22.88
Price Avg 50: 19.04   Price Avg 200: 16.49
Volume: 166482   Average Volume: 107579

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Log in — it's free
See in Nexus

Relevant news

Anika Therapeutics, Inc. (ANIK) Q3 2026 Earnings Call Transcript
06-11-2026 13:04
Anika Therapeutics, Inc. (ANIK) Q3 2026 Earnings Call Transcript
Anika Therapeutics (ANIK) Beats Q3 Earnings and Revenue Estimates
06-11-2026 09:25
Anika Therapeutics (ANIK) Beats Q3 Earnings and Revenue Estimates
Anika (ANIK) Is a Great Choice for 'Trend' Investors, Here's Why
24-08-2026 09:57
Anika (ANIK) Is a Great Choice for 'Trend' Investors, Here's Why
Anika Stock Gains 43.4% in the Past 3 Months: Here Is Why?
21-08-2026 12:41
Anika Stock Gains 43.4% in the Past 3 Months: Here Is Why?
Anika Therapeutics (ANIK) Is Up 11.10% in One Week: What You Should Know
14-08-2026 13:01
Anika Therapeutics (ANIK) Is Up 11.10% in One Week: What You Should Know
5 Stocks With Recent Price Strength to Tap August Rally
10-08-2026 10:25
5 Stocks With Recent Price Strength to Tap August Rally

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Pricing

How MarketSnap works

What’s new

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
      • Large Caps
      • Absolute
      • Total Market PE
      • Large Caps
      • Absolute
      • Industry
      • Sector
    • Analyze a stockAnalyze ANIK →
    • FindStock Picks / Stock Screener
    • Value · ANIKIntrinsic Value Calculator
    • Invest · ANIKInvestment Case
    • Hold · ANIK5-Year Outlook
  • Learn
  • Calendar
  • Investment Compounding Calculator
    • Charts
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Investing Philosophy
  • Nexus
    • Recent Activity
      • Overview
      • My Valuations
      • My Investment Journal
      • Watchlists & Portfolio
    • Plans
    • Settings
    • Public profile ↗
  • Log in
  • Log out

Media

Watch Listen Read
Ask MarketSnap AI

MarketSnap AI Assistant

Uses MarketSnap data and this page

Ready

🔒 You are currently logged out

Login

It's free

MarketSnap Assistant · Tips
    MarketSnap

    Welcome to MarketSnap

    The AI-powered workspace for stock pickers.

    Continue with Google Continue with email

    Already a member? Sign in

    Find stocks·Value them·Build the case·Journal decisions·Track what changes

    Free to join. No card needed. Privacy Policy

    Create your free MarketSnap account Continue with Google
    Chat with us MarketSnap support · account, plans, settings, help
    How MarketSnap works

    The conversation above goes to the MarketSnap team with your message. We reply by e-mail.